液体活检技术的进展及其对胰腺癌的影响。
Advances in Liquid Biopsy Technology and Implications for Pancreatic Cancer.
发表日期：2023 Feb 20
作者：
Alexander G Raufi, Michael S May, Matthew J Hadfield, Attila A Seyhan, Wafik S El-Deiry
来源：
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
摘要：
胰腺癌是一种高度侵袭性的恶性肿瘤，发病率逐渐上升。大多数病例在晚期发现，伴有不可治愈的局部晚期或转移性疾病。即使是接受手术切除的人，复发率也非常高。目前没有普遍接受的筛查方式适用于普通人群，而且诊断、评估治疗反应和复发检测主要依赖于影像学的使用。迫切需要识别出微创技术来帮助诊断、预后、预测治疗反应或耐药性以及检测复发。液体活检代表了一种新兴的技术组，可以进行非侵入性的肿瘤物质连续取样。尽管液体活检平台的敏感性和特异性还未被批准用于胰腺癌的常规使用，但现代液体活检平台的不断改进将有可能在不久的将来改变临床实践。在本综述中，我们将讨论液体活检的最新技术进展，重点关注循环肿瘤DNA、外泌体、微RNA和循环肿瘤细胞。
Pancreatic cancer is a highly aggressive malignancy with a climbing incidence. The majority of cases are detected late, with incurable locally advanced or metastatic disease. Even in individuals who undergo resection, recurrence is unfortunately very common. There is no universally accepted screening modality for the general population and diagnosis, evaluation of treatment response, and detection of recurrence relies primarily on the use of imaging. Identification of minimally invasive techniques to help diagnose, prognosticate, predict response or resistance to therapy, and detect recurrence are desperately needed. Liquid biopsies represent an emerging group of technologies which allow for non-invasive serial sampling of tumor material. Although not yet approved for routine use in pancreatic cancer, the increasing sensitivity and specificity of contemporary liquid biopsy platforms will likely change clinical practice in the near future. In this review, we discuss the recent technological advances in liquid biopsy, focusing on circulating tumor DNA, exosomes, microRNAs, and circulating tumor cells.